Federal grants to Fox Chase Chemical Diversity Center Inc.
Fox Chase Chemical Diversity Center Inc. in Doylestown, Pennsylvania received $21.6 million in federal grants from fiscal 2021 to 2025, across 11 awards. Its largest program was Allergy and Infectious Diseases Research, with $13.5 million. In fiscal 2025 it was awarded $3.4 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$21.6 million
- Awards11
- Awarded in FY 2025$3.4 million
- Largest award$7.4 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 6 | $4.0 million |
| FY 2022 | 6 | $5.1 million |
| FY 2023 | 6 | $5.0 million |
| FY 2024 | 4 | $4.1 million |
| FY 2025 | 3 | $3.4 million |
Programs that fund Fox Chase Chemical Diversity Center Inc.
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 9 | $13.5 million |
| Aging Research | 1 | $7.4 million |
| Cardiovascular Diseases Research | 1 | $794,716 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 11 | $21.6 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Therapeutics targeting TDP-43 to treat alzheimer's disease and related disorders - TDP-43 is a mixed proteinopapthy in alzheimer’s disease (AD), ad-tdp, based on substantial epidemiological data correlating TDP-43 inclusions with cognitive decline in ad patients. TDP-43 associated ad has been termed | Aging Research | June 23, 2021 | $7.4 million |
| Trypanocidal agents that kill multiple stages of the trypanosoma cruzi life cycle - abstract. Chagas disease is a neglected tropical disease and has been designated as a research priority by niaid and an sbir research topic of interest. Six million individuals are infected and 8,000 deaths were caus | Allergy and Infectious Diseases Research | April 7, 2023 | $3.0 million |
| Optimizing a stapled-peptide that specifically targets HSV-1 to treat herpes ocular keratitis - abstract infection of the eye by herpes simplex VIRUS-1 (HSV-1) can result in herpes keratitis (HK), which is the leading cause of infectious corneal blindness worldwide. In the U.S., nearly 500,000 indiv | Allergy and Infectious Diseases Research | June 21, 2022 | $3.0 million |
| Development of small molecule therapeutics targeting hemorrhagic fever viruses - summary: the ultimate goal of this phase II application is to develop novel small molecule, broad-spectrum therapeutics against viral infections caused by filoviruses, arenaviruses, and other viruses that depend on the | Allergy and Infectious Diseases Research | March 8, 2021 | $3.0 million |
| Development of a peptide-drug conjugate for topically treating the viral skin disease molluscum contagiosum - abstract molluscum contagiosum (MC) is a highly contagious skin disease caused by the poxvirus, mcv. It remains an unmet medical need due to lack of an approved antiviral drug. Mc appears as | Allergy and Infectious Diseases Research | July 31, 2024 | $2.0 million |
| Small molecule antagonists of PF4 for the treatment and prevention of hit | Cardiovascular Diseases Research | June 2, 2021 | $794,716 |
| Development of a peptide-drug conjugate for topically treating the viral skin disease molluscum contagiosum - abstract molluscum contagiosum (MC) is a highly contagious skin disease caused by the poxvirus, mcv. It remains an unmet medical need due to lack of an approved antiviral drug. Mc appears as | Allergy and Infectious Diseases Research | April 19, 2021 | $606,500 |
| Development of host- oriented therapeutics targeting severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), - the ultimate goal of this phase i application is to discover and develop host-oriented small molecule compounds targeting severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) | Allergy and Infectious Diseases Research | August 22, 2022 | $598,928 |
| Development of fosa inhibitors to potentiate fosfomycin activity in gram-negative pathogens - summary. Antimicrobial resistance is widely recognized as one of the most significant public health threats of the century. Many bacterial infections have become difficult to treat due to antimicrobial resi | Allergy and Infectious Diseases Research | August 15, 2022 | $598,124 |
| Trypanocidal agents that kill multiple stages of the trypanosoma cruzi life cycle | Allergy and Infectious Diseases Research | June 17, 2021 | $299,999 |
Questions people ask
How much federal grant money does Fox Chase Chemical Diversity Center Inc. get?
$21.6 million in 11 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Fox Chase Chemical Diversity Center Inc. the most?
The Department of Health and Human Services, with $21.6 million in 11 awards.
What is Fox Chase Chemical Diversity Center Inc.'s largest federal grant?
$7.4 million under Aging Research, with its first action in the period on June 23, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Fox Chase Chemical Diversity Center Inc.?
Its largest are Allergy and Infectious Diseases Research, Aging Research and Cardiovascular Diseases Research.
Other grant recipients in Doylestown
- Bucks, the County of
- Bucks County Intermediate Unit 22
- Bucks County Housing Authority
- Delaware Valley University
- River Crossing Young Men's Christian Association
- Baruch S. Blumberg Institute
- Evrys Bio, Inc.
- Imcare Biotech, Inc.
Largest federal grant recipients in Pennsylvania · Federal grants in Pennsylvania